Know Cancer

or
forgot password


Phase 2
20 Years
N/A
Open (Enrolling)
Both
Squamous NSCLC

Thank you

Trial Information


Inclusion Criteria:



- histologically confirmed squamous NSCLC

- Previously treated with one or two lines of chemotherapy

- FGFR amplification (FISH > 5 copies of genes)

- 20 years or older

- ECOG PS 0-2

Exclusion Criteria:

- active infection

- uncontrolled brain metastasis

- unstable angina or MI

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

response rate

Outcome Time Frame:

6 months

Safety Issue:

No

Principal Investigator

Myung-Ju Ahn

Investigator Role:

Principal Investigator

Investigator Affiliation:

Samsung Medical Center

Authority:

Korea: Food and Drug Administration

Study ID:

2012-09-070-002

NCT ID:

NCT01861197

Start Date:

March 2013

Completion Date:

Related Keywords:

  • Squamous NSCLC
  • Efficacy
  • Dovitinib
  • Squamous NSCLC
  • Carcinoma, Non-Small-Cell Lung

Name

Location